NEW YORK, Oct. 21, 2019 /PRNewswire/ -- In collaboration with Cook Children's Hospital and the UN, the 2019 C3 US-Arab Healthcare and Business Summit proudly featured His Excellency Dr. Abdullatif bin Rashid Al-Zayan, Secretary-General of the Gulf Cooperation Council, as their Keynote Speaker. As with past years, the Summit was held on open

BOCA RATON, Fla., Oct. 21, 2019 /PRNewswire/ -- Beacon of Hope CRO, which helps companies provide safe, ethical and legal patient access to their investigational treatments outside of traditional clinical trials, is changing its name to Access Hope CRO.Access Hope CRO is the first contract research organization exclusively dedicated to providing the infrastructure

LENEXA, Kan., Oct. 21, 2019  /PRNewswire/ -- After guiding Lakeview Village through the last 10 years as President and Chief Executi

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning or

MELBOURNE, Australia, Oct. 21, 2019 /PRNewswire/ -- Veritas Health Innovation Ltd is pleased to announce that it has received grant funding of AU$2,000,000 to support its mission to bring research into practice faster than ever before. The grant comes from three leading Australian foundations: The Ian Potter Foundation, the Lord Mayor's Charitable Foundation and the

NEW YORK, Oct. 21, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution.

SAN FRANCISCO, Oct. 21, 2019 /PRNewswire/ -- Amygdala Neurosciences (a private company) has been awarded up to $1.35 million NIH grant support for the project titled "26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies.

BARCELONA, Spain, Oct. 21, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study. The data demonstrated that the majority of adult patients with moderately to severely active ulcerative colitis who achieved symptomatic remission1 with STE

CARLSBAD, Calif., Oct. 21, 2019 /PRNewswire/ -- For biological researchers looking to reduce their reliance on cold storage without disrupting their existing workflow, Thermo Fisher Scientific's new cell culture media are the first to remain stable at room temperature.

LONG BEACH, Calif., Oct. 21, 2019 /PRNewswire/ -- SCAN Health Plan®, one of the nation's largest not-for-profit Medicare Advantage plans, has earned a 4.5-star rating*